EnteroMedics Stock Price, News & Analysis (NASDAQ:RSLS)

$1.36 0.03 (2.26 %)
(As of 12/17/2017 04:00 PM ET)
Previous Close$1.36
Today's Range$1.35 - $1.41
52-Week Range$1.23 - $30.41
Volume186,190 shs
Average Volume416,456 shs
Market Capitalization$29.54 million
P/E RatioN/A
Dividend YieldN/A
Beta2.97

About EnteroMedics (NASDAQ:RSLS)

EnteroMedics logoReShape Lifesciences Inc., formerly EnteroMedics Inc., is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company's neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company's initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company's VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

Receive RSLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorHealthcare
SymbolNASDAQ:RSLS
CUSIP29365M20
Phone+1-651-6343003

Debt

Debt-to-Equity RatioN/A
Current Ratio6.20%
Quick Ratio5.82%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$790,000.00
Price / Sales37.39
Cash FlowN/A
Price / CashN/A
Book Value$1.07 per share
Price / Book1.27

Profitability

Trailing EPS($5.90)
Net Income$-23,360,000.00
Net Margins-4,509.61%
Return on Equity-104.23%
Return on Assets-90.59%

Miscellaneous

Employees32
Outstanding Shares21,720,000

EnteroMedics (NASDAQ:RSLS) Frequently Asked Questions

What is EnteroMedics' stock symbol?

EnteroMedics trades on the NASDAQ under the ticker symbol "RSLS."

When did EnteroMedics' stock split? How did EnteroMedics' stock split work?

EnteroMedics's stock reverse split on Friday, January 8th 2016. The 1-15 reverse split was announced on Wednesday, December 23rd 2015. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 7th 2016. An investor that had 100 shares of EnteroMedics stock prior to the reverse split would have 7 shares after the split.

How were EnteroMedics' earnings last quarter?

EnteroMedics Inc. (NASDAQ:RSLS) issued its quarterly earnings results on Tuesday, November, 14th. The medical device company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.29) by $0.77. The medical device company earned $0.36 million during the quarter. EnteroMedics had a negative return on equity of 104.23% and a negative net margin of 4,509.61%. View EnteroMedics' Earnings History.

When will EnteroMedics make its next earnings announcement?

EnteroMedics is scheduled to release their next quarterly earnings announcement on Tuesday, March, 6th 2018. View Earnings Estimates for EnteroMedics.

Where is EnteroMedics' stock going? Where will EnteroMedics' stock price be in 2017?

1 equities research analysts have issued twelve-month price targets for EnteroMedics' shares. Their forecasts range from $11.00 to $11.06. On average, they expect EnteroMedics' stock price to reach $11.03 in the next year. View Analyst Ratings for EnteroMedics.

Who are some of EnteroMedics' key competitors?

Who are EnteroMedics' key executives?

EnteroMedics' management team includes the folowing people:

  • Dan W. Gladney, Chairman of the Board, President, Chief Executive Officer (Age 64)
  • Scott P. Youngstrom, Chief Financial Officer, Chief Compliance Officer (Age 57)
  • Naqeeb A. Ansari, Senior Vice President - Sales (Age 56)
  • Paul F. Hickey, Senior Vice President - Marketing and Reimbursement (Age 52)
  • Peter M. Delange, Senior Vice President - Operations and Business Development (Age 48)
  • Gary D. Blackford, Director (Age 60)
  • Michael Y. Mashaal M.D., Director (Age 43)
  • Lori Courtney McDougal, Director (Age 56)
  • Bobby I. Griffin, Independent Director (Age 79)
  • Jon T. Tremmel, Independent Director (Age 70)

How do I buy EnteroMedics stock?

Shares of EnteroMedics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EnteroMedics' stock price today?

One share of EnteroMedics stock can currently be purchased for approximately $1.36.

How big of a company is EnteroMedics?

EnteroMedics has a market capitalization of $29.54 million and generates $790,000.00 in revenue each year. The medical device company earns $-23,360,000.00 in net income (profit) each year or ($5.90) on an earnings per share basis. EnteroMedics employs 32 workers across the globe.

How can I contact EnteroMedics?

EnteroMedics' mailing address is 2800 Patton Rd, SAINT PAUL, MN 55113-1100, United States. The medical device company can be reached via phone at +1-651-6343003 or via email at [email protected]


MarketBeat Community Rating for EnteroMedics (RSLS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  247
MarketBeat's community ratings are surveys of what our community members think about EnteroMedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

EnteroMedics (NASDAQ:RSLS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.03$8.35$8.35$8.35
Price Target Upside: 118.42% upside65.41% upside65.41% upside65.41% upside

EnteroMedics (NASDAQ:RSLS) Consensus Price Target History

Price Target History for EnteroMedics (NASDAQ:RSLS)

EnteroMedics (NASDAQ:RSLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$11.00LowView Rating Details
1/9/2017S&P Equity ResearchLower Price Target$17.19 -> $11.06N/AView Rating Details
6/9/2016Roth CapitalDowngradeBuy -> Neutral$3.00 -> $3.00N/AView Rating Details
(Data available from 12/17/2015 forward)

Earnings

EnteroMedics (NASDAQ:RSLS) Earnings History and Estimates Chart

Earnings by Quarter for EnteroMedics (NASDAQ:RSLS)

EnteroMedics (NASDAQ RSLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/6/2018        
11/14/2017Q3($0.29)($1.06)$0.36 millionViewN/AView Earnings Details
8/8/2017Q2 2017($1.00)($0.91)$0.20 million$0.09 millionViewListenView Earnings Details
5/16/2017Q1 2017($0.63)($1.27)$0.04 millionViewN/AView Earnings Details
3/7/2017Q4 2016($0.44)($2.65)$0.14 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.50)($0.17)$0.34 million$0.30 millionViewN/AView Earnings Details
8/4/2016Q216($0.75)($0.49)$0.19 million$0.28 millionViewN/AView Earnings Details
2/17/2016Q315($0.90)($0.95)$0.43 million$0.15 millionViewListenView Earnings Details
8/6/2015Q215($0.10)($0.10)$0.06 million$0.08 millionViewN/AView Earnings Details
2/18/2015Q414($0.10)($0.09)ViewN/AView Earnings Details
11/12/2014Q3 14($0.10)($0.08)ViewN/AView Earnings Details
8/7/2014Q2($0.10)($0.11)ViewListenView Earnings Details
4/30/2014Q1 14($0.10)($0.10)ViewN/AView Earnings Details
2/12/2014Q413($0.10)($0.11)ViewN/AView Earnings Details
10/31/2013Q313($0.11)($0.11)ViewN/AView Earnings Details
7/31/2013Q2 2013($0.13)($0.11)ViewN/AView Earnings Details
5/1/2013Q1 2013($0.13)($0.14)$0.10 millionViewN/AView Earnings Details
2/13/2013Q4 2012($0.14)($0.17)$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

EnteroMedics (NASDAQ:RSLS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.97 EPS
Next Year EPS Consensus Estimate: $-0.7 EPS

Dividends

Dividend History for EnteroMedics (NASDAQ:RSLS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

EnteroMedics (NASDAQ RSLS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 26.40%
Institutional Ownership Percentage: 0.75%
Insider Trades by Quarter for EnteroMedics (NASDAQ:RSLS)

EnteroMedics (NASDAQ RSLS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017Carl GoldfischerDirectorSell4,668$4.85$22,639.80View SEC Filing  
6/3/2016Peter M DelangeSVPBuy20,000$0.55$11,000.00View SEC Filing  
8/13/2015Mark B KnudsonCEOBuy303,000$0.25$75,750.00View SEC Filing  
6/19/2014Cathy FriedmanDirectorBuy11,800$1.70$20,060.00View SEC Filing  
1/8/2014Luke EvninDirectorSell556,585$2.50$1,391,462.50View SEC Filing  
2/27/2013Anthony P JanszDirectorBuy150,000$0.95$142,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

EnteroMedics (NASDAQ RSLS) News Headlines

Source:
DateHeadline
ReShape Lifesciences Announces Stocking Order from Medical Supplier in DubaiReShape Lifesciences Announces Stocking Order from Medical Supplier in Dubai
finance.yahoo.com - December 13 at 9:00 AM
EnteroMedics (RSLS) Lowered to Sell at Zacks Investment ResearchEnteroMedics (RSLS) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 6 at 6:02 AM
ReShape Lifesciences Announces Coverage of ReShape Dual Balloon by Major Telecom CompanyReShape Lifesciences Announces Coverage of ReShape Dual Balloon by Major Telecom Company
finance.yahoo.com - December 4 at 8:42 AM
Comparing EnteroMedics (RSLS) and Its PeersComparing EnteroMedics (RSLS) and Its Peers
www.americanbankingnews.com - December 3 at 11:10 PM
EnteroMedics (RSLS) Raised to "Hold" at ValuEngineEnteroMedics (RSLS) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - December 2 at 6:56 PM
Head-To-Head Analysis: EnteroMedics (RSLS) versus Its CompetitorsHead-To-Head Analysis: EnteroMedics (RSLS) versus Its Competitors
www.americanbankingnews.com - November 30 at 7:24 PM
Critical Contrast: EnteroMedics (RSLS) and The CompetitionCritical Contrast: EnteroMedics (RSLS) and The Competition
www.americanbankingnews.com - November 30 at 11:18 AM
Reviewing EnteroMedics (RSLS) and Its PeersReviewing EnteroMedics (RSLS) and Its Peers
www.americanbankingnews.com - November 25 at 9:18 PM
EnteroMedics (RSLS) vs. Its Competitors Head to Head AnalysisEnteroMedics (RSLS) vs. Its Competitors Head to Head Analysis
www.americanbankingnews.com - November 24 at 9:12 PM
EnteroMedics Inc. (RSLS) Downgraded by Zacks Investment Research to HoldEnteroMedics Inc. (RSLS) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - November 22 at 7:18 PM
Comparing EnteroMedics (RSLS) and Its RivalsComparing EnteroMedics (RSLS) and Its Rivals
www.americanbankingnews.com - November 22 at 1:22 PM
EnteroMedics (RSLS) & Its Competitors Head-To-Head AnalysisEnteroMedics (RSLS) & Its Competitors Head-To-Head Analysis
www.americanbankingnews.com - November 17 at 5:28 PM
EnteroMedics Inc. (RSLS) Posts Quarterly  Earnings Results, Misses Expectations By $0.77 EPSEnteroMedics Inc. (RSLS) Posts Quarterly Earnings Results, Misses Expectations By $0.77 EPS
www.americanbankingnews.com - November 14 at 9:34 PM
ReShape Lifesciences Announces Third Quarter 2017 Financial ResultsReShape Lifesciences Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 8:44 PM
EnteroMedics Inc. (RSLS) to Release Quarterly Earnings on TuesdayEnteroMedics Inc. (RSLS) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 7 at 9:06 AM
EnteroMedics (RSLS) vs. The Competition Head-To-Head ReviewEnteroMedics (RSLS) vs. The Competition Head-To-Head Review
www.americanbankingnews.com - November 5 at 3:26 AM
ReShape Lifesciences Presents New Data on Obesity TechnologiesReShape Lifesciences Presents New Data on Obesity Technologies
finance.yahoo.com - November 4 at 12:44 PM
Rising P/E: An Overlooked Way to Reach 5 Winning Stocks - NasdaqRising P/E: An Overlooked Way to Reach 5 Winning Stocks - Nasdaq
www.nasdaq.com - November 1 at 3:20 PM
Rising P/E: An Overlooked Way to Reach 5 Winning StocksRising P/E: An Overlooked Way to Reach 5 Winning Stocks
finance.yahoo.com - November 1 at 8:14 AM
ReShape Lifesciences To Host Third Quarter Conference Call On November 14, 2017ReShape Lifesciences To Host Third Quarter Conference Call On November 14, 2017
finance.yahoo.com - November 1 at 8:14 AM
Financial Comparison: Dynatronics Corporation (DYNT) & EnteroMedics (RSLS)Financial Comparison: Dynatronics Corporation (DYNT) & EnteroMedics (RSLS)
www.americanbankingnews.com - October 30 at 1:28 PM
PerkinElmer (PKI) vs. EnteroMedics (RSLS) Financial AnalysisPerkinElmer (PKI) vs. EnteroMedics (RSLS) Financial Analysis
www.americanbankingnews.com - October 25 at 7:12 AM

SEC Filings

EnteroMedics (NASDAQ:RSLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

EnteroMedics (NASDAQ:RSLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

EnteroMedics (NASDAQ RSLS) Stock Chart for Sunday, December, 17, 2017

Loading chart…

This page was last updated on 12/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.